arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

ANI Pharmaceuticals, Inc.

ANIP Health Care Biotechnology: Pharmaceutical Preparations
$71.23
Today
as of Sep 4, 16:45 ET
Last 30 days -12.11% Jul 28 → Sep 04
$70.32 $73.62 $76.93 $80.24 $83.54 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$71.35
High
$72.06
Low
$71.11
Volume
$219,215
Avg Vol
$381,646
Mkt Cap
$1.8B
P/E (TTM)
20.59
Beta
—
52w High
$99.50
52w Low
$70.15
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

Sep 4 · 22:14 Simply Wall St.
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
Sep 3 · 10:55 PR GlobeNewswire
ANI Pharmaceuticals to Present at September Investor Conferences
Aug 27 · 23:45 StockStory
2 Reasons to Like ANIP (and 1 Not So Much)
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$70
$100
4% of range
Avg surprise (last 3)
+45.3%
Avg reaction (last 2)
-4.9%
0% positive
Latest IV / EM
48%
EM ±7.5% · $70 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.27$-0.53$0.21$0.94$1.68 Actual $0.06Actual $0.29Actual $0.45Actual $0.82Actual $-0.14Actual $-1.27Actual $1.37Est $1.09Actual $1.38Est $1.02Actual $1.13Actual $1.68Est $0.96Actual $1.05 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-24M$52M$128M$203M$279M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $1.05 — — — — financials
Fri May 8, 2026Mar/2026 $1.68 $0.96 +75.0% +22.6% -2.4% earnings
Tue Sep 30, 2025Sep 2025 $1.13 — — — — financials
Fri Aug 8, 2025Jun/2025 $1.38 $1.02 +35.3% — — earnings
Fri May 9, 2025Mar/2025 $1.37 $1.09 +25.7% — -7.3% earnings
Mon Sep 30, 2024Sep 2024 $-1.27 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.14 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.82 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.45 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.29 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.06 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$266M$237M—$228M$211M$197M—$148M
Cost of revenue————————
Gross profit————————
Operating income$40M$39M—$36M$14M$26M—$-21M
Net income$25M$29M—$27M$9M$16M—$-24M
EPS (diluted)$1.05$1.28—$1.13$0.36$0.69—$-1.27

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$360M$311M$286M$263M$218M$150M$145M$145M
Inventory$143M$143M$143M$146M$138M$137M$137M$148M
Total current assets$825M$747M$753M$698M$603M$536M$528M$521M
Total assets$1.49B$1.42B$1.44B$1.41B$1.34B$1.29B$1.28B$1.29B
Long-term debt$280M$286M$292M$298M$301M$305M$309M$313M
Total liabilities$897M$860M$900M$902M$881M$849M$855M$857M
Total equity$597M$562M$541M$506M$437M$419M$404M$406M

Implied volatility — last 90 days

30%62%94%126%157% Jun 07 — IV 53% · EM ±7.3%Jun 08 — IV 51% · EM ±6.7%Jun 09 — IV 52% · EM ±6.5%Jun 10 — IV 69% · EM ±8.2%Jun 11 — IV 64% · EM ±7.1%Jun 12 — IV 71% · EM ±7.2%Jun 15 — IV 101% · EM ±7.3%Jun 16 — IV 102% · EM ±6.0%Jun 19 — IV 47% · EM ±10.3%Jun 22 — IV 47% · EM ±9.8%Jun 23 — IV 39% · EM ±8.0%Jun 24 — IV 38% · EM ±7.5%Jun 25 — IV 37% · EM ±7.3%Jun 26 — IV 34% · EM ±6.6%Jun 29 — IV 39% · EM ±7.0%Jun 30 — IV 54% · EM ±9.2%Jul 01 — IV 45% · EM ±7.5%Jul 02 — IV 38% · EM ±6.1%Jul 03 — IV 39% · EM ±6.1%Jul 06 — IV 42% · EM ±5.9%Jul 07 — IV 48% · EM ±6.4%Jul 08 — IV 47% · EM ±5.8%Jul 09 — IV 44% · EM ±5.2%Jul 10 — IV 39% · EM ±4.3%Jul 13 — IV 75% · EM ±6.3%Jul 14 — IV 85% · EM ±6.1%Jul 15 — IV 104% · EM ±6.1%Jul 16 — IV 146% · EM ±6.1%Jul 20 — IV 52% · EM ±12.3%Jul 21 — IV 54% · EM ±12.6%Jul 22 — IV 53% · EM ±12.2%Jul 23 — IV 52% · EM ±11.7%Jul 24 — IV 54% · EM ±11.8%Jul 27 — IV 55% · EM ±11.5%Jul 28 — IV 53% · EM ±10.9%Jul 29 — IV 56% · EM ±11.2%Jul 30 — IV 53% · EM ±10.4%Jul 31 — IV 53% · EM ±10.1%Aug 03 — IV 58% · EM ±10.3%Aug 04 — IV 60% · EM ±10.4%Aug 05 — IV 54% · EM ±9.0%Aug 06 — IV 62% · EM ±10.0%Aug 07 — IV 35% · EM ±5.5%Aug 10 — IV 37% · EM ±5.1%Aug 12 — IV 42% · EM ±5.3%Aug 13 — IV 56% · EM ±6.6%Aug 14 — IV 59% · EM ±6.5%Aug 17 — IV 78% · EM ±6.5%Aug 18 — IV 90% · EM ±6.5%Aug 19 — IV 109% · EM ±6.4%Aug 20 — IV 158% · EM ±6.6%Aug 24 — IV 33% · EM ±6.8%Aug 25 — IV 30% · EM ±6.2%Aug 26 — IV 31% · EM ±6.2%Aug 27 — IV 31% · EM ±6.2%Aug 28 — IV 32% · EM ±6.2%Aug 31 — IV 39% · EM ±6.9%Sep 01 — IV 52% · EM ±9.0%Sep 02 — IV 56% · EM ±9.3%Sep 03 — IV 62% · EM ±10.1%Sep 04 — IV 48% · EM ±7.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in